Two preclinical platforms

The Myeloïd platform aims at optimizing the therapeutic potential of myeloid cells in immuno-oncology and immuno-inflammation. In resolving inflammation, OSE-230 is a first agonist antibody to the ChemR23 target, expressed on myeloid cells, and has been developed with the ability to resolve chronic inflammation by driving affected tissues to complete the inflammation program and restore tissue integrity. These results, published preclinically for several chronic inflammatory pathologies, make it a first clinical candidate for a new therapeutic class.

In collaboration with the CRTI (Center for Research in Transplantation and Immunology, Nantes), the Company has characterized CLEC-1 (a C-type lectin receptor) as a novel myeloid immune checkpoint and validated the first monoclonal antibody antagonists of CLEC-1 as an innovative new potential therapeutic in cancer immunotherapy.

The BiCKI® platform in immuno-oncology, is an anti-PD-1 platform merged with innovative immunotherapy targets. Preclinical efficacy studies with BiCKI®-IL-7 were presented at international congresses. This first bifunctional therapy targets PD-1 and simultaneously delivers the cytokine IL-7. This product is able to restore the function of exhausted T lymphocytic cells, a frequent cause of clinical escape of anti-PD1. It increases T stem cells capable of reconstituting memory and effector T cells to increase antitumor efficacy.


To receive OSE Immunotherapeutics’ latest news